Dose Escalation Revumenib for Leukemia

"The primary objective of this research endeavor, spanning up to a 12-week period, is to evaluate the incidence of Dose Limiting Toxicity (DLT) among the study participants. Secondary endpoints encompass determining the rate at which patients achieve Measurable Residual Disease Negative (MRD-) status following induction and consolidation chemotherapy using flow cytometry for MRD assessment. Additionally, another secondary endpoint involves assessing Molecular Measurable Residual Disease Negative (MRD-) rates post-induction chemotherapy through NPM1 and FLT3 ITD MRD testing alongside duplex sequencing methodologies."

"Information available on clinicaltrials.gov reveals that this particular research project is presently not accepting new participants. Initially listed on 9/1/2024 and last revised on 3/10/2024, the study has concluded recruitment efforts. Nonetheless, there are currently 1551 alternative trials actively seeking eligible candidates for participation."

"Our team at Power rated the safety level of Dose Escalation Revumenib as 1 on a scale from 1 to 3. This trial falls under Phase 1, indicating that there is minimal existing data supporting both safety and efficacy."

"To qualify for this trial, participants must have a diagnosis of acute myeloid leukemia and fall between the ages of 18 and 75. The study aims to enroll approximately 22 individuals."

"In this research study, participation is open to individuals over 18 years of age and under the age of 75."